Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Cancer Immunol Res. 2014 Aug 12;2(11):1071–1079. doi: 10.1158/2326-6066.CIR-14-0005

Figure 5. Treatment of human MCC tumors with intralesional IFN-β is associated with MHC-I upregulation.

Figure 5

Clinical details of patient 1 (not including immunologic studies) were reported previously (30). After IFN- β monotherapy, patient 1 subsequently experienced 8+ years of disease-free survival. Three patients that received intralesional IFN injections as part of their MCC treatment who had specimens available from before and after IFN treatment are shown. A significant increase in MHC-I expression was observed on tumor cells after treatment (p=0.04; paired t-test).